Notably, VEGF TKIs and PD‐1/PD‐L1 immune checkpoint inhibitors have emerged as potent therapeutic options, demonstrating remarkable efficacy in the treatment of ccRCC [38, 39, 40]. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.